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Abstract
Objectives: The aim of  this age-matched, controlled, prospective clinical study was to investigate  frequency  and degree 
of  erectile  dysfunction  (ED) in patients  with obstructive sleep apnea syndrome (OSAS) and to evaluate the results of  only 
continuous positive airway pressure (CPAP) therapy on ED in patients with OSAS.
Materials  and Methods:  A total of  90 patients were evaluated for potential OSAS. They were  given  an  International  In-
dex  of   Erectile  Function  questionnaire  (IIEF)  and  Beck Depression Inventory. Sixty-two patients with the diagnosis of  
OSAS were regarded as study group. Twenty-eight patients in whom the OSAS was excluded, were regarded as the control 
group. Biochemical  and hormonal laboratory evaluation  were performed.  Then all patients underwent  a full-night  in lab-
oratory  polysomnography  examination.  The degree  of  OSAS were evaluated by an expert from chest diseases department.
Results: When compared to the control group, a decrease in IIEF-5 scores was found in patients with OSAS. However, this 
decrease was not statistically significant. After 3 months of  CPAP usage in patients with mild to moderate and severe degree 
OSAS, improvement  in IIEF-5 scores was statistically significant. Mean value of  IIEF-5 score was 16.63±5.91 before CPAP 
and were improved up to 20.92±6.79 (P=0.001).
Conclusion:  It is not certainly  possible  to say that OSAS  is clearly  associated  with ED. However, after 3 months of  
regular CPAP usage, ED complaints in patients with OSAS might improve positively. Trials with larger series may give more 
conclusive data.
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Introduction
Erectile dysfunction (ED) is defined  as the inability 
to initiate and  continue  sufficient erection in order 
to permit satisfactory sexual performance1. This situa-
tion is connected with both  physical and psychosocial 
health and plays an important role in the  quality of  
life of  affected men and their partners. In Turkey, the 
prevalence of    ED has been reported   as 69.2% in the 
study that evaluated 1982 men2.
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Obstructive sleep apnea syndrome (OSAS) should be 
defined as, the recurrent complete (apnea) or partial 
(hypopnea) episodes of  upper respiratory tract obstruc-
tion, and it is often characterized by a decrease in blood 
oxygen saturation3. This is one of  the most common 
sleep disorders. The prevalence was considered as 1-5% 
for men and 1.2 to 2.5% for  women in  the  adult  pop-
ulation.  The  prevalence  increases  with  age4.  In  a 
study  conducted  in Turkey, the prevalence of  OSAS 
was found to be as 0.9- 1.9%5.
Studies  on  the  patients  with  OSAS  demonstrated 
that  the    apneas  and  hypopneas occuring during the 
sleep period caused hypoxemia, then hypoxemia caused 
the activation of  the sympathetic nervous system that 
concomitantly induced cardiovascular system disorders. 
Consequently, oxidative stress impaired hypothalam-
ic-gonadal axis and lead to psychological depression 
and  decreased  libido.  In addition,  fatigue,  decrease 
in   Rapid  Eye  Movement (REM) sleep period and 
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neurogenic dysfunction all provoked the deterioration 
in the quality of   erection6-8. So, via above etiologic fac-
tors, OSAS may lead to ED in men.
Treatment of   patients with OSAS may be classified 
under five headings;1 lifestyle changes,2 medical treat-
ment, 3 surgical treatment,4 oral cavity tools and,5 con-
tinous positive airway pressure  (CPAP) therapy. Cur-
rently, CPAP therapy was regarded as the gold standard 
treatment. In a  study  concerning the results of  CPAP 
treatment  performed  on  ED patients with OSAS,  Pe-
rimenis et al. compared the results of   CPAP therapy 
with combined therapy (CPAP plus sildenafil therapy). 
They achieved better results with combined therapy 
9. In our country, in 2008, a study was performed  by 
Taskin  et al. including 17 men with severe OSAS10. 
A statistically significant improvement concerning the 
IIEF scores after one  month  of   CPAP  therapy  was 
noticed.  They  concluded  that  the  CPAP  therapy 
was effective in the treatment of  ED. Recently, Shin et 
al., evaluated the effects of  surgical (uvulopalatophar-
yngoplasty)  and  non-surgical  approaches  (CPAP  and 
mandibular advancement devices) on ED and quality 
of  life in 56 cases with OSAS11. Patients were evaluat-
ed with the Korean version of  IIEF-5 after treatment. 
However, significant increase in IIEF-5 score was only 
observed in surgically treated group. In 2013, Budweis-
er et al. assessed the changes  in sexual function  in men 
with OSAS after CPAP therapy12. CPAP users (n=21) 
experienced  an  improvement  in  overall  sexual  func-
tion  (IIEF-15  summary  score) when compared to 
CPAP non-users (n=18). In contrast to the findings of  
Shin et al., they concluded that CPAP treatment can im-
prove sexual function.
Similarly, in our study, the frequency of  ED in  OSAS 
patients was investigated  using control  groups.  We 
also formed  groups  from  mild-moderate  and severe 
OSAS   cases.  In addition, we  aimed  to evaluate the 
possible effects of  CPAP therapy  on IIEF scores. For 
this purpose, we tried to compare the  pre-treatment 
IIEF scores with post-treatment IIEF scores that were 
held in third month after treatment. 
 
Materials and methods
The study was approved by the Research Ethics Board 
of  our University hospital and all patients signed con-
sent forms to participate in the study. Between the pe-
riod September 2011-  June  2012,  90 patients  who 
applied  to   the  “sleep  disorders  polyclinic”  of    chest 
diseases department of  our Faculty with the pre-diag-
nosis   of  sleep apnea were involved in the study. All 
patients were subjected to polysomnography test.
The patients  were hospitalized along one night (be-
tween the hours of   11:00 pm to 6:00 a.m) in  the  sleep 
laboratory  equipped  with  PSG  devices  -Compu-
medics,  Melbourne, Australia- and -Respironics,  Mur-
rysville, PA, USA-, and at least 7 hours of  polysom-
nographic record was obtained. Electroencephalogram, 
elektrooculogram, electromyogram,  and  an  electro-
cardiogram  results  were  also  recorded.  The  respira-
tion  of  patients was monitored by nasal cannula. Chest 
and abdominal movements,  body position, oxygen 
saturation  and  snoring  sounds  were  recorded.  Pol-
ysomnography   results     were evaluated   by an expert 
(T.Ö.; R.A.)   according  to the the classification   based 
on   2008 American Academy Sleep Criteria (AASM). 
Apnea means a respiratory arrest   at least 10 seconds 
or more; but hypopnea expresses a condition in which 
the respiration continues at least 10 seconds and the 
flow decreases  50%     and   saturation  drops   3 units, 
or   30% decrease of   flow and  a decline of   4 units in 
saturation.
The sum of   the  Episodes  of  apnea and  hypopnea 
was considered  as   apnea-hypopnea index (AHI). AHI 
between 5-14 (including 5) plus at least one symptom 
(snoring, witnessed apnea, excessive daytime sleepiness) 
was  considered as “mild OSAS”. AHI score between 
15-29  (including 15) was considered as “moderate 
OSAS”, and  cases with AHI over 30 were assessed as 
“severe OSAS”.   After polysomnography,  the   pa-
tients   with an AHI   score of  less than 5 were regarded 
as control group.
CPAP usage indications  according to  AASM 2008  re-
port were considered as; AHI ≥ 15  / hour    or AHI 
≥ 5 plus  the  presence  of  major/obvious  symptoms, 
cardiovascular  or cerebrovascular  risk  factors  (hyper-
tension,  stroke,  excessive  daytime  sleepiness,  ischem-
ic heart disease, insomnia) and existence of    mental 
disorders13.
CPAP titration was done in an another day for the pa-
tients  in whom treatment  was planned according  to 
the AHI scores. Titration was carried out   by   an auto-
matic   CPAP device (Weinmann, Hamburg, Germany).
In  the  urology  clinic  of   our  hospital,  urologists 
evaluated  the  ED  complaints  and possible effects 
of  CPAP treatment. In all cases, a detailed medical and 
sexual history was taken. The patient's age, presence of  
erectile dysfunction complaints, the presence of  early 
and late ejaculation, smoking and alcohol consumption, 
the presence of  a systemic diseases, drug use/abuse, 
physical  activity  and  socio-economic   status  were 
questioned  and  recorded. Detailed physical exami-
nation was performed in all patients and the 15-item 
questionnaire International Index of  Erectile Function 
(IIEF) was completed. IIEF evaluates five domains of  
sexual function. These are   erectile function (6 ques-
tions), orgasmic function (2 questions), sexual desire (2 
questions), intercourse satisfaction (3 questions), and 
overall satisfaction (2 questions).  Later, a short five-
item version of  the 15-item IIEF was developed (IIEF-
5) to diagnose the presence and severity of  ED. IIEF-5 
classifies the ED intensity as mild, moderate or severe.
Beck Depression Scale (BDI) was filled in all men who 
participated in the study. BDI form consists of  21 ques-
tions and  commonly used to evaluate the psychological 
status of  the patient. After the diagnosis of  OSAS, 28 
men were subjected to 3-month CPAP therapy. At the 
end of  the therapy, IIEF-15 form was also completed.
The thyroid function, fasting blood glucose, total cho-
lesterol, LDL, HDL, triglycerides, and total testoster-
one tests were all made in all men. Height and weight of  
all patients were measured and Body Mass Index (BMI) 
was calculated for each patient. The calculation was 
made by the formula of   BMI = [weight (kg)/ height 
(m) ²].
The patients using nitrates, phosphodiesterase type 5 
inhibitors and psychotropic medications; patients with 
hormonal disorders, neuropathic disease, prostate can-
cer, patients with a history of  pelvic trauma, renal trans-
planted patients, patients with aortic aneurysms, spinal 
cord injury, penile deformities, alcohol dependence, 
acute and chronic psychiatric disorders, metabolic and 
neurological diseases were excluded from the study.
The packaged  software of   SPSS 13.0 was used  in 
the  statistical analysis of   this study. The Categorical 
variables in the data set were given with the frequen-
cy and percentage,  and constant  value  measurement 
variables  were  given  together  with  the  average, 
standard deviation,  median,  minimum  and  maximum 
values.  The  Compliance  of   the  continous variables 
with the normal distribution was controlled   by the 
Shapiro Wilk test. One-way variance  analysis    was 
used  for  the comparison  of  3  groups  with  normally 
distributed variables. Kruskal-Wallis test was used for 
the comparison of   3 groups   with   abnormally dis-
tributed  variables, and Mann-Whitney U  test was used 
for the comparison of  2 groups. Pearson's  Chi-Square 
test was used for group  comparisons  of  categorical 
variables.  In all analysis, a p value less than 0.05 was 
considered as statistically significant. 
 
Results
According to the results of  polysomnography, 90 pa-
tients with OSAS were divided into 3 groups.   Men 
with an AHI   score of    less than 5 were regarded 
as control group (n=28; Group 1). Men suffering 
from mild/moderate OSAS were regarded as Group 2 
(n=29), while men with severe OSAS were included in 
Group 3 (n=33).   All men were requested to fill IIEF-5 
questionnaire. The CPAP therapy was applied to a total 
of  28 patients. After 3 months of  therapy, they were 
requested to fill the questionnaire again. Demographic 
data and clinical parameters  for all groups with relevant 
p values were given in Table 1. Age groups were simi-
lar in each groups. No statistically significant difference 
was noticed when the presence of   smoking and alcohol 
use, diabetes mellitus, hypertension, cardiovascular dis-
ease and loss of   libido  were  compared  between  the 
groups  (p>  0.05,  chi-square  test).  In  addition,  no 
difference was observed when groups were compared 
in terms of  daily physical activity and socioeconomic 
status.  When  groups  were  compared  in  terms  of  
BDI  scores,  hormonal (thyroid function tests and se-
rum testosterone levels) and biochemical (total choles-
terol, LDL, HDL, triglycerides, fasting blood glucose) 
parameters, no statistically significant difference was 
observed (p> 0.05; Kruskal-Wallis test) (Table 1).
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Table 1. Clinical parameters for all groups with relevant p values 
 
 Group 1 (n=28) Group 2 (n=29) Group 3 
(n=33) 
p value 
Age (years)* 46,07 ±12,74 48,97 ±11,3 48,85 ±10,96 0.569** 
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IIEF-5 score* 23,46±5,27 21,82±6,05 19,90±7,05 0.085† 
                  *Values are presented as means ± standard deviations and range 
** One-way ANOVA 
† Kruskal Wallis test 
‡ Chi-square test 
IIEF: International Index of Erectile Function 
BDI: Beck Depression Scale 
TSH: Thyroid stimulating hormone 
BMI: Body Mass Index
No correlation was observed  between BMI and IIEF-5 
scores (p = 0,148, r = 0.154). When the patients  were 
assessed on the basis of    IIEF-5 scores, changes in 
IIEF-5 scores after 3-month CPAP therapy and rele-
vant p values were given in Table 2.
As seen in Table 3, we observed  that   the mean min-
imum  (min) and average  (ave) oxygen saturation val-
ues in each groups were significantly different between 
each group  (p =0.001, Mann-Whitney U test). When 
the patients were classified into 2 groups according to 

































              * Wilcoxon Signed Rank test 
ave oxygen saturation values ≤89% (n=19; mean IIEF-
5 score=17,89±7,89)  and above 89% (n=43; mean 
score=22,09±5,60); statistically significant difference 
in terms of   IIEF-5 scores were noticed (p=0.049; 
Mann-Whitney U test).
Table 3: Minimum (Min) and Average (Ave) oxygen saturation values according to groups 
 
 Min O2 saturation 
(%) 
Ave O2 saturation (%) p* value 
Group 1 89,75±3,02 
(median:90) 




Group 2 83,17±4,30 
(median:83) 
92,20±1,89 (median:92) 






               * Mann Whitney U test 
The average AHI in groups 1,2 and 3 were 2.72 ± 
1.43 (median value: 2.72); 19.84 ± 5.66 (median  value: 
20.90)  and,  58.71  ± 19.48 (median  value:  52), respec-
tively.  A weak negative  correlation    between  AHI 
and  IIEF-5    scores  were  documented  in  correlation 
analysis  (p = 0.013, r = 0.262). 
 
Discussion
Various  studies  searched  the relation  between  ED 
and OSAS  since  1970’s14-18. However, very few of  
these studies examined simultaneously depression 
which is one of  the most important reasons for ED as 
well. Also, in only a few studies, the change in erectile 
function  after  CPAP  treatment  in  OSAS  cases  were 
searched.  Our  main  aim  in  this prospective study 
was to compare the relation between ED and OSAS in 
a selective group of  patients.
 
CPAP therapy is regarded as the gold standard treat-
ment by pulmonologists in OSAS treatment19. We start-
ed 3-month-CPAP therapy in 28 OSAS cases with cer-
tain indications (AHI ≥ 15 / hour  or AHI ≥ 5 plus 
the presence of  major/obvious symptoms, cardiovas-
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cular or cerebrovascular  risk factors   and existence  of  
mental disorders)  . We preferred  3-month therapy, be-
cause; after literature review, we concluded that the op-
timum duration for clinical improvement was defined 
as 3 months20,21.
In  2005,  Gonçalves  et al.  examined  erectile  function 
in  patients  with  OSAS  who received CPAP treatment 
for a period of  one month22. They evaluated 98 patients 
and, found out that ED in patients with OSAS was re-
lated with nocturnal hypoxemia. In our study, nocturnal 
hypoxemia has been searched similarly with oxygen sat-
uration values measured all through the night. When the 
cut-off  value for average oxygen saturation values was 
taken as 89% for nocturnal  hypoxemia;  mean IIEF-
5 scores of  patients with nocturnal hypoxemia were 
statistically significantly lower than those of  patients 
without nocturnal hypoxemia. We think that, recurrent 
apnea attacks in patients with OSAS cause hypoxia rep-
erfusion injury and  oxidative  stress,  release  of   oxy-
gen  radicals  and  endothelial-derived  nitric  acid  and 
disruptions  in  its  function  concomitantly.  So,  via 
the  effect  on  NO  pathway,  nocturnal hypoxemia may 
cause ED23.
Depression  is the most important  psychiatric  disorder 
that may cause ED in patients with OSAS. No statisti-
cally significant difference was determined in terms of  
BDI among patient groups. Similarly, when control and 
study groups were compared, no statistical significancy 
was documented. So, we think  that inter-group  vari-
abilities  in terms  of  BDI scores were minimized. For 
example, if  we had a group with a significantly higher 
BDI score; IIEF score for that group would probably 
be affected, and this would be a limiting factor in the 
evaluation  of  the relation between  ED and OSAS. Be-
cause depression  is a major risk factor for ED. 
 
One of  the most extensive prevalence studies search-
ing the relation between ED and OSAS is the one con-
ducted by Andersen et al24. Totally 467 men ranging in 
age from 20 to 80 have been included in this epidemi-
ological study. When parameters that could effect ED 
were examined with logistic regression model, they ob-
served that obesity (odds ratio =1.8), low testosterone 
level (odds ratio= 4.28), disrupted life quality (odds ra-
tio:4.4), AHI over 15 (odds ratio=2.75) and OSAS di-
agnosis (odds ratio= 2.13) were predictive for ED. In 
current study,  no statistically significant difference was 
determined between study groups when the average 
IIEF-5 scores were compared. Although, the p value 
was insignificant among groups, there  were  a tendency 
to lower  IIEF-5  scores  when  the OSAS  severity  de-
gree  increased (Table 1). So, for us,  it is not possible to 
say that OSAS severity is a strong determinant for ED.
For today, age is regarded as the most important deter-
minant in ED etiopathogenesis. Odds ratio for age was 
21,65 in the study conducted by Andersen et al24.  This 
means that men over 50 have approximately 21 times 
higher risk for ED than those men in ages between 20-
30. Since our study was age matched, in our study, we 
were able to eliminate the most important determinant 
in ED etiology.
When the current literature was reviewed, there were 
also studies which showed no relation between OSAS 
and ED18,25,26. Schiavi et al. investigated nocturnal penile 
tumescence in 70 men with polysomnographic study 
that lasted all through the night for four days and found 
no relation between sleep apnea and ED26. In addition, 
285 men with ED were examined in a study conducted 
by Seftal et al. A survey searching OSAS risk factors was 
made with those patients. According to the results of  
this study; despite various sleep disorders were deter-
mined in patients with ED, no correlation regarding the 
relation between OSAS and ED was found27. However, 
it should be kept in mind that, OSAS investigation was 
based on a survey and, no polysomnographic  evalua-
tion was made in this study. Later, Margel  et al., exam-
ined  209 patients  similarly through sleep questioning 
survey and IIEF questionnaire,  and all patients  were 
subjected  to polysomnographic  evaluation28.  They 
determined decrease in IIEF scores in patients with 
OSAS, however this decrease was not statistically sig-
nificant. They determined statistically significant IIEF 
decrease only in patients with severe OSAS. In contrast 
with the findings of  Margel et al., in our study, average 
IIEF-5 scores in men with severe OSAS (group 3) were 
not significantly different from group 1 and group 2. 
However,  there  was  a  tendency  to decrease  in IIEF-
5  scores  when  the  OSAS severity increased. 
 
Nasal CPAP treatment is effective in patients with 
OSAS. An interesting study was carried out by Peri-
menis et al.29. In this study, patients with OSAS and ED 
who received - only CPAP- treatment were compared 
with -sildenafil plus CPAP- treatment. They found that 
sildenafil  treatment  administered  together  with CPAP 
is more effective  than -only CPAP- treatment.  ED de-
gree in patients with severe sleep apnea  was also inves-
tigated by Taskin et al., and possible benefits of  CPAP 
treatment on ED were searched10. Fourty patients with 
severe OSAS were randomized into 2 treatment groups. 
While men in the first group were treated  with  CPAP 
therapy,  men  in  the  second  group  were  treated  with 
antidepressant medication for one month. Mean IIEF-
5 score reached 19.06 from 15.71 in the first group, and 
this increase was statistically significant. We evaluated 
men with OSAS after "3-month" CPAP treatment.  We 
believed that "1-month"  CPAP treatment would not be 
sufficient for clinical improvement in ED. As seen in Ta-
ble 2, mean IIEF-5 score, which was 16.45 before CPAP 
treatment,  reached  to  20.54  after  treatment  of   pa-
tients  with  mild-moderate  OSAS (group 2) (p=0.005). 
When the patients with severe OSAS were examined, 
the average IIEF-5 score increased up to 21.17 which 
was 16.70 before the treatment (p= 0.001). Taskin and 
colleagues examined  patients with severe OSAS only. 
In addition,  we also examined men with mild-moderate 
OSAS. According to the results of  our study, we can say 
that, men with mild or moderate  OSAS may also ben-
efit from 3-month-CPAP  treatment  as patients with 
severe OSAS.
In  our  opinion,  if   men  with  OSAS  suffer  from  ED, 
CPAP  treatment  should  be effective. CPAP therapy 
combined with oral sildenafil treatment may even be 
more beneficial as Perimenis et al. previously suggested 
29. On contrary to this opinion, 60 patients with OSAS 
were treated with CPAP in a study carried out by Mar-
gel et al. and long term effects of  this treatment  were 
searched.  Interestingly,  IIEF-5  scores  decreased  after 
CPAP  treatment30.  In  other  words,  they  concluded 
that  CPAP  treatment  may  disrupt  erectile  function 
instead of  improving.  But, as Taskin et al. already im-
plied in their articles, we think that, CPAP   treatment 
was  not  administered   sufficiently   in  this  study. 
Margel   et  al.  just administered "one hour CPAP treat-
ment in a week". However, in our study, CPAP therapy 
was administered "every night for 3 months". We be-
lieve that, intensive CPAP treatment is necessary espe-
cially in patients with severe OSAS in order to decrease 
ED complaints.
Both total and free testosterone levels were lower in 
patients with OSAS according to the  results  of   the 
study  that  was  carried  out  by  Gambineri  et  al31.  In 
contrast,  no statistically significant difference was de-
termined in terms of  total testosterone among groups 
 
in our study (Table 1). Thus, current study data does 
not support the hypothesis that OSAS decreases the se-
rum testosterone level.
Several limitations of  the present study should be con-
cerned. Although, all polysomnographic measurements 
and evaluations  were made by the same   pulmonolo-
gists (T.O.;R.A.) who were blinded to the IIEF results 
and erectile capacity of  men in the study groups, the 
evaluation of  erectile dysfunction and depression via 
IIEF and BDI questionnaires still remain subjective as-
sessment  modalities.  But, for today, IIEF is regarded 
as a widely used, multi-dimensional self-report instru-
ment for the evaluation of  male sexual function and, is 
accepted as the "gold-standard"  measure for efficacy 
assessment in clinical trials of  ED32. Same is true for 
the BDI questionnaire33. Secondly,  our sample size is 
not large enough to make a discrete conclusion. Unfor-
tunately, to the best of  our knowledge, no prospective, 
randomized age-matched clinical trial with larger series 
has been published evaluating the results of  CPAP ther-
apy on ED in patients with OSAS. Further studies fo-
cused on this subject may give more conclusive data.
Conclusion
OSAS is not clearly associated with ED. However,  after 
3 months of  regular CPAP usage, ED complaints in 
patients with OSAS improve positively. Oxygen satura-
tion  measurements  throughout  the night, which was 
one of  the most important  tests searching nocturnal 
hypoxemia, may reveal how much the patient remained 
hypoxic during the night. In current study, mean IIEF-
5 scores were lower in men with nocturnal hypoxemia. 
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